Blood serum antibody analysis and long-term follow-up of patients treated with recombinant human bone morphogenetic protein-2 in the lumbar spine

Spine

Volumn 36, Issue 25, 2011, Pages 2158-2167

  Burkus, J Kenneth ^a   Gornet, Matthew F ^b   Glassman, Steven D ^c   Slosar, Paul J ^d   Rosner, Michael K ^e   Deckey, Jeffrey E ^f   Nowak, John ^g   Hatcher, Brian M ^h  

^a HUGHSTON CLINIC   (United States)

^b Spine Institute ^*

^c Spine Institute   (United States)

^d SpineCare Medical Group   (United States)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

^f Orthopaedic Specialty Institute   (United States)

^g PFIZER INC   (United States)

^h Medtronic Spinal and Biologics   (United States)

Author keywords

antibody formation; BMP 2; bone morphogenetic protein; degenerative disc disease; INFUSE Bone Graft; lumbar fusion; lumbar spine; spinal arthrodesis

Indexed keywords

COLLAGEN SPONGE; NEUTRALIZING ANTIBODY; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

ANTERIOR SPINE FUSION; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTHRODESIS; ARTICLE; BONE GRAFT; CERAMICS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; ILIAC CREST; LUMBAR SPINE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SPINE FUSION; SPINE SURGERY; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES; ANTIBODIES, NEUTRALIZING; BONE MORPHOGENETIC PROTEIN 2; CATTLE; COLLAGEN TYPE I; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERVERTEBRAL DISC; INTERVERTEBRAL DISC DEGENERATION; LONGITUDINAL STUDIES; LUMBAR VERTEBRAE; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; SPINAL FUSION; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 81855163368     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3182059a8c     Document Type: Article

References (43)

1. Heller S, Kozlovski P, Kurtzhals P. Insulin's 85th anniversary-an enduring medical miracle. Diabetes Res Clin Pract 2007;78:149-58.
2. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86.
3. Baskin DS, Ryan P, Sonntag V, et al. A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine 2003;28:1219-24; discussion 1225.
4. Burkus JK, Heim SE, Gornet MF, et al. Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device. J Spinal Disord Tech 2003;16:113-22.
5. Burkus JK, Sandhu HS, Gornet MF, et al. Use of rhBMP-2 in combination with structural corticalallografts: Clinicaland radiographic outcomes in anterior lumbar spinal surgery. J Bone Joint Surg Am 2005;87:1205-12.
6. Burkus JK, Transfeldt EE, Kitchel SH, et al. Clinicaland radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2. Spine 2002;27:2396-408.
7. Dimar JR, Glassman SD, Burkus JK, et al. Clinicaland radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral spine arthrodesis. J Bone Joint Surg Am 2009;91:1377-86.
8. Friedlander GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001;83(suppl 1)(Pt 2):S151-8.
9. Govender S, Csimma C, Genant HK, et al. BMP-2 evaluation in surgery for tibial trauma. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: A prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002;84:2123-34.
10. Jones AL, Bucholz RW, Bosse MJ, et al. Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am 2006;88:1431-41.
11. Vaccaro AR, Patel T, Fischgrund J, et al. A pilot study evaluating the safety and efficacy of OP-1 Putty (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis for degenerative spondylolisthesis. Spine 2004;29:1885-92.
12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
13. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
14. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
15. Mitchell JD, Wokke JH, Borasio GD. Recombinant human insulinlike growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev 2007;(4):CD002064.
16. Locatelli F, Vecchio LD. Darbepoetin alfa. Amgen. Curr Opin Investig Drugs 2001;2:1097-104.
17. Reyes-Ruiz JM, Barrera-Saldana HA. Proteins in a DNA world: Expression systems for their study. Rev Invest Clin 2006;58:47-55.
18. Leader B, Baca QJ, Golan DE. Protein therapeutics: A summary and pharmacological classification. Nat Rev Drug Discov 2008;7:21-39.
19. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006;21(suppl 5):v9-12.
20. OP-1 Putty [package insert]. Hopkinton, MA: Stryker Biotech LLC; 2004.
21. Enbrel [package insert]. Thousand Oaks, CA, and Collegeville, PA: Amgen and Wyeth Pharmaceuticals; 2006.
22. Humatrope [package insert]. Indianapolis, IN: Eli Lilly & Co; 2006.
23. Gupta S, Indelicato SR, Jethwa V, et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 2007;321:1-18.
24. Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004;289:1-16.
25. Vaccaro AR, Lawrence JP, Patel T, et al. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft for posterolateral lumbar arthrodesis: A long-term (4 years) pivotal study. Spine 2008;33:2850-62.
26. Gornet MF, Burkus JK, Mathews HH, et al. Maverick™ total disc replacement versus anterior lumbar interbody fusion with the INFUSE® Bone Graft /LT-CAGE® device: A prospective, randomized, controlled, multicenter IDE trial. [Abstract]. In: Proceedings of the 22nd Annual Meeting of the North American Spine Society. Spine J 2007;7:1S.
27. Rosen V, Nove J, Song JJ, et al. Responsiveness of clonal limb bud cell lines to bone morphogenetic protein 2 reveals a sequential relationship between cartilage and bone cell phenotypes. J Bone Miner Res 1994;9:1759-68.
28. Gazzerro E, Canalis E. Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 2006;7:51-65.
29. Porter S: Human immune response to recombinant human proteins. J Pharm Sci 2001;90:1-11.
30. Schellekens H: Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther 2002;24:1720-40.
31. Shankar G, Shores E, Wagner C, et al. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol 2006;24:274-80.
32. Boyne PJ, Lilly LC, Marx RE, et al. De novo bone induction by recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillary sinus floor augmentation. J Oral Maxillofac Surg 2005;63:1693-707.
33. Fiorellini JP, Howell TH, Cochran D, et al. Randomized study evaluating recombinant human bone morphogenetic protein-2 for extraction socket augmentation. J Periodontol 2005;76:605-13.
34. Barnes B, Boden SD, Louis-Ugbo J, et al. Lower dose of rhBMP-2 achieves spine fusion when combined with an osteoconductive bulking agent in non-human primates. Spine 2005;30:1127-33.
35. Glassman SD, Dimar JR, Carreon LY, et al. Initial fusion rates with recombinant human bone morphogenetic protein-2/compression resistant matrix and a hydroxyapatite and tricalcium phosphate/collagen carrier in posterolateral spinal fusion. Spine 2005;30:1694-8.
36. Louis-Ugbo J, Kim HS, Boden SD, et al. Retention of 125I-labeled recombinant human bone morphogenetic protein-2 by biphasic calcium phosphate or a composite sponge in a rabbit posterolateral spine arthrodesis model. J Orthop Res 2002;20:1050-9.
37. McKay W, Peckham S, Marotta J. The Science of rhBMP-2. St Louis, MO: Quality Medical Publishing Inc; 2006.
38. INFUSE Bone Graft [package insert]. Memphis, IN: Medtronic Spinal Biologics; 2002.
39. Schellekens H. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther 2002;24:1720-40; discussion 1719.
40. American Pregnancy Association. Available at: Http://www. americanpregnancy. org. Accessed August 21, 2008.
41. Singh K, Dumonski M, Stanley T, et al. Repeat use of human recombinant bone morphogenetic protei n-2 for second level lumbar arthrodesis. Spine 2001;36:192-6.
42. Carreon LY, Glassman SD, Brock DC, et al. Adverse events in patients re-exposed to bone morphogenetic protein for spine surgery. Spine 2008;33:391-3.
43. Kuklo T, Bridwell K, Cillo Y. Is there a clinically detectable response to repeat use of rhBMP-2 in the spine? Presented at: 22nd Annual Meeting of the North American Spine Society; October 24-27, 2007; Austin, TX.